Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam將通過網絡直播電話會議討論2024年第二季度財務業績
Jul 18, 2024
2024 年 7 月 18 日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 18, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open.
馬薩諸塞州劍橋--(美國商業資訊)--2024年7月18日--領先的RNAi治療公司Alnylam Pharmicals, Inc.（納斯達克股票代碼：ALNY）今天宣佈，將在美國金融市場開放之前，即2024年8月1日星期四公佈截至2024年6月30日的第二季度財務業績。
Management will provide an update on the Company and discuss second quarter 2024 results as well as expectations for the future via conference call on Thursday, August 1, 2024 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at . An archived webcast will be available on the Alnylam website approximately two hours after the event.
管理層將在美國東部時間2024年8月1日星期四上午 8:30 通過電話會議介紹公司的最新情況，討論2024年第二季度的業績以及對未來的預期。電話會議的網絡直播將在公司網站的 “投資者” 部分播出，網址爲。活動結束大約兩小時後，將在Alnylam網站上提供存檔的網絡直播。
About Alnylam Pharmaceuticals
關於 Alnylam 製藥
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.
Alnylam（納斯達克股票代碼：ALNY）領導了將RNA干擾（RNAi）轉化爲一種全新的創新藥物，有可能改變患有罕見和流行病但需求未得到滿足的人們的生活。基於諾貝爾獎得主的科學，RNAi療法代表了一種強大的、經過臨床驗證的方法，可以產生革命性的藥物。自2002年成立以來，Alnylam一直領導着RNAi革命，並繼續實現將科學可能性變爲現實的大膽願景。Alnylam的商用RNAi治療產品是ONPATTRO（patisiran）、AMVUTTRA（vutrisiran）、GIVLAARI（givosiran）、OXLUMO（lumasiran）和Leqvio（inclisiran），後者由Alnylam的合作伙伴諾華開發和商業化。Alnylam擁有大量在研藥物，包括多種處於後期開發階段的候選產品。Alnylam正在執行其 “Alnylam P5x25” 戰略，通過可持續創新和卓越的財務業績，提供針對罕見和常見疾病的變革性藥物，使全球患者受益，從而形成領先的生物技術地位。Alnylam總部位於馬薩諸塞州劍橋。如需了解有關我們的員工、科學和渠道的更多信息，請通過 X（前身爲 Twitter）@Alnylam、LinkedIn 或 Instagram 訪問並與我們互動。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Alnylam 製藥公司
克里斯汀·里根·林登布姆
（投資者和媒體）
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
喬什·布羅德斯基
（投資者）
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
來源：Alnylam Pharmicals, Inc.